Respiratory

Pleural effusion: thoracentesis and Light's criteria

Clinical Overview and When to Suspect Pleural Effusion

— Heart failure (most common transudate)

— Pneumonia/parapneumonic (most common exudate)

— Malignancy (lung, breast, lymphoma, mesothelioma)

— Pulmonary embolism (can be either, usually exudate)

— Cirrhosis with hepatic hydrothorax, nephrotic syndrome, PD-related

— Dyspnea + dullness to percussion + decreased breath sounds

— Worsening hypoxia in a CHF patient despite diuresis

— Persistent fever after 48–72h of antibiotics for pneumonia (think empyema)

— Recurrent unilateral effusion in a smoker (malignant until proven otherwise)

— Post-CABG patient with left-sided effusion weeks after surgery

Board pearl: A unilateral effusion in a CHF patient that fails to resolve after 3 days of adequate diuresis is not simply "CHF effusion" — tap it. Hidden malignancy, PE, or empyema lurk here disproportionately on exam stems.

Definition: abnormal accumulation of fluid in the pleural space (>10–20 mL beyond physiologic). Classified physiologically as transudate (imbalance of hydrostatic/oncotic pressures) or exudate (increased capillary permeability or impaired lymphatic drainage).

Epidemiology in U.S. practice: ~1.5 million new effusions yearly. Top causes:

When to suspect on Step 3 stems:

Initial threshold to image: any unexplained dyspnea or asymmetric breath sounds in inpatient or ambulatory setting → upright PA/lateral CXR. Blunting of the costophrenic angle requires ~200–500 mL fluid on PA; lateral decubitus detects as little as 50 mL.

Decision pivot: Once effusion is confirmed, the next question is do I tap it? — most new, clinically significant effusions of unclear etiology require diagnostic thoracentesis. Exceptions: small (<10 mm on decubitus or US), classic bilateral CHF responding to diuresis, or hepatic hydrothorax already explained.

Presentation Patterns and Key History

— Dyspnea (most common; severity correlates with volume and rate of accumulation more than absolute size)

— Pleuritic chest pain — sharp, worse with inspiration; suggests parietal pleural involvement (inflammation, infection, malignancy, PE infarct)

— Dry cough from mechanical compression

— Orthopnea if large enough to compromise diaphragmatic excursion

— Orthopnea, PND, leg edema, prior MI → CHF transudate

— Fever, productive cough, recent pneumonia → parapneumonic/empyema

— Weight loss, smoking, hemoptysis, prior cancer → malignant effusion

— Asbestos exposure (shipyard, insulation, brake repair) → mesothelioma or benign asbestos pleural effusion

— Ascites, jaundice, alcohol use → hepatic hydrothorax (usually right-sided)

— Recent CABG → post-cardiac injury syndrome (Dressler-like, left-sided, 3 weeks–months out)

— Pancreatitis or esophageal rupture → left-sided exudate with high amylase

— Recent travel, immobilization, OCP, malignancy → PE-related effusion

— Tuberculosis exposure, immigration from endemic area, HIV → TB pleuritis (lymphocyte-predominant, high ADA)

— RA, SLE → rheumatologic effusion (RA: very low glucose, low pH)

Step 3 management: In the ambulatory clinic, a patient with a new asymptomatic small effusion found incidentally on CXR needs a structured history focused on CHF risk, malignancy red flags, recent infection, and asbestos exposure — these four buckets cover >90% of stems. Document weight loss, fevers, and functional status before deciding outpatient vs hospital workup.

Core symptoms:

History clues that steer etiology:

Medication history: amiodarone, methotrexate, nitrofurantoin, dasatinib, minoxidil — all can cause drug-induced pleural disease.

Occupational/social: asbestos latency 20–40 years; ask about household contacts too.

Physical Exam Findings and Hemodynamic Assessment

— Decreased chest wall expansion on affected side

— Tachypnea, accessory muscle use if large

— JVD, peripheral edema → favors transudate (CHF)

— Stigmata of cirrhosis (spider angiomata, caput, ascites) → hepatic hydrothorax

— Cachexia, supraclavicular nodes → malignancy

— Decreased tactile fremitus over the effusion (fluid dampens vibration)

— Tracheal deviation away from a massive effusion (contrast with atelectasis, which pulls toward)

— Dullness to percussion — the most reliable bedside sign

— Stony dull classic for large effusion

— Decreased or absent breath sounds

— Egophony ("E to A" change) and bronchial breath sounds just above the effusion from compressive atelectasis

— Pleural friction rub if dry pleuritis coexists

— Most effusions are hemodynamically benign, but a massive effusion (>1500 mL) can cause tamponade-like physiology of the contralateral structures: hypotension, tachycardia, pulsus paradoxus, mediastinal shift on imaging

— Tension hydrothorax is rare but a true emergency → immediate drainage

Key distinction: Dullness + decreased fremitus + decreased breath sounds = effusion. Dullness + increased fremitus + bronchial breath sounds = consolidation. Hyperresonance + decreased fremitus + decreased breath sounds = pneumothorax. This triad-matrix is a perennial exam trap; memorize the fremitus direction as the discriminator between effusion and pneumonia.

Board pearl: Bedside ultrasound now outperforms percussion — anechoic space with "spine sign" (visible thoracic vertebrae above the diaphragm) confirms effusion and is the standard pre-thoracentesis check in U.S. inpatient practice.

Inspection:

Palpation:

Percussion:

Auscultation:

Hemodynamic assessment:

Diagnostic Workup — Initial Imaging and Labs

— PA upright: blunting of costophrenic angle (~200 mL), meniscus sign

— Lateral: posterior costophrenic blunting detected at ~50–75 mL

— Lateral decubitus: layering >10 mm = tappable; gold standard plain film for small effusions

— Supine films underestimate — only show diffuse haziness

— Detects as little as 5–20 mL

— Distinguishes free-flowing vs loculated

— Identifies septations (suggest exudate/empyema)

— Marks safe needle entry → reduces pneumothorax risk by ~50%, now required by patient-safety standards before thoracentesis

CCS pearl: On a CCS case, order in this sequence: CXR PA/lateral → bedside US → thoracentesis with simultaneous serum protein/LDH/glucose/albumin → pleural fluid studies. Skipping the serum draw is the most common CCS error; without it you cannot apply Light's criteria and you'll lose timing points.

Board pearl: A NT-proBNP in the pleural fluid >1500 pg/mL strongly supports CHF as the cause even when Light's criteria misclassify it as exudate (occurs in ~25% of diuresed CHF patients).

Chest X-ray (first test):

Bedside thoracic ultrasound (preferred and increasingly standard):

CT chest with contrast: indicated when malignancy, empyema, or PE suspected; identifies pleural thickening, nodularity, "split pleura sign" of empyema, mediastinal adenopathy, parenchymal disease.

Basic labs before tap: CBC, CMP (albumin, LDH for serum comparison), coagulation panel, BNP if cardiac. No absolute INR/platelet cutoff per current society guidance, but most operators hold tap if INR >1.5 or plt <50k unless urgent. Routinely correcting mild coagulopathy is not required.

Serum studies to send same day as tap: total protein, LDH, glucose, albumin — needed to calculate Light's criteria and gradients.

Diagnostic Workup — Pleural Fluid Analysis and Light's Criteria

— Pleural protein / serum protein >0.5

— Pleural LDH / serum LDH >0.6

— Pleural LDH >2/3 upper limit of normal serum LDH

— Serum–pleural protein gradient >3.1 g/dL → transudate (CHF, post-diuresis)

— Serum–pleural albumin gradient >1.2 g/dL → transudate

— Pleural NT-proBNP >1500 pg/mL → CHF

— Glucose <60 mg/dL: empyema, RA (often <30), TB, malignancy, lupus, esophageal rupture

— pH <7.20: complicated parapneumonic → needs drainage; also low in empyema, RA, malignancy, esophageal rupture

— Amylase elevated: pancreatitis, esophageal rupture (salivary isoform), malignancy

— Triglycerides >110 mg/dL: chylothorax (thoracic duct injury, lymphoma)

— Hematocrit pleural/serum >0.5: hemothorax → chest tube

— Cell count differential:

– Neutrophil-predominant: parapneumonic, PE, pancreatitis

– Lymphocyte-predominant (>50%): TB, malignancy, post-CABG, chylothorax

– Eosinophils >10%: air or blood in pleural space, drug reaction, asbestos, parasites

— Adenosine deaminase >40 U/L: TB pleuritis (high sensitivity in endemic settings)

— Cytology: ~60% sensitivity single tap for malignancy; repeat increases yield

— Gram stain/culture, AFB, fungal as indicated

Key distinction: pH <7.20 OR glucose <60 OR positive Gram stain/culture OR loculation in a parapneumonic effusion = complicated → needs tube thoracostomy, not just antibiotics. This is the single highest-yield management trigger on Step 3 pulmonology stems.

Light's criteria — fluid is exudate if any one is met:

Sensitivity ~98% for exudate; specificity ~80%. Misclassifies ~25% of CHF effusions as exudates, especially after diuresis.

Rescue tests when Light's says exudate but you suspect transudate:

Additional fluid tests (order based on suspicion):

Risk Stratification and Management Logic

— <10 mm on decubitus/US in a stable patient with obvious cause (CHF) → treat cause, no tap

— Otherwise → diagnostic thoracentesis

— Transudate → treat underlying systemic cause (diuresis for CHF, salt restriction/TIPS evaluation for hepatic hydrothorax, dialysis optimization for renal)

— Exudate → narrow differential by fluid characteristics

— Category 1 — uncomplicated: small (<½ hemithorax), free-flowing, pH >7.20, glucose >60, Gram stain negative → antibiotics alone

— Category 2 — borderline: moderate size, pH 7.00–7.20 or LDH >1000 → antibiotics + therapeutic tap

— Category 3 — complicated: pH <7.00, positive Gram stain, loculation → chest tube + antibiotics

— Category 4 — empyema: frank pus → chest tube + antibiotics ± intrapleural tPA/DNase ± VATS

— Diagnostic + therapeutic tap; recurrence is the rule

— Recurrent symptomatic → indwelling pleural catheter (IPC) or chemical pleurodesis (talc)

Step 3 management: For a hospitalized pneumonia patient whose effusion grows on repeat imaging or who remains febrile at 48–72 h, the correct next step is repeat imaging + thoracentesis with pH — not broadening antibiotics. Missing a complicated parapneumonic effusion is the most common pneumonia-management pitfall on the exam.

Step 1 — Is the effusion clinically significant or diagnostic?

Step 2 — Transudate vs exudate (Light's criteria):

Step 3 — Parapneumonic effusion staging (ACCP):

Step 4 — Malignant effusion:

Therapeutic drainage limit: historically ≤1500 mL per session to avoid re-expansion pulmonary edema, but current data suggest drainage can continue until symptomatic chest discomfort, persistent cough, or pleural pressure < −20 cm H₂O if manometry used.

Pharmacotherapy — Treating the Underlying Cause

— IV loop diuretic (furosemide 20–40 mg IV, titrate to 2.5× home dose), monitor I/O, weight, K⁺, Mg²⁺, Cr

— Add GDMT: ARNI/ACEi/ARB, beta-blocker, MRA, SGLT2 inhibitor — addresses both effusion recurrence and mortality

— Salt restriction <2 g/day, fluid <2 L/day

— Community-acquired: ceftriaxone + metronidazole, OR ampicillin-sulbactam, OR levofloxacin + metronidazole — must cover anaerobes

— Hospital-acquired/post-aspiration with risk factors: piperacillin-tazobactam or carbapenem; add vancomycin/linezolid if MRSA risk

— Duration: 2–6 weeks depending on drainage adequacy and clinical response; longer for empyema

— Avoid aminoglycosides — poor pleural penetration and inactivated by low pH

— Sodium restriction + spironolactone + furosemide (100:40 ratio)

— Avoid chest tubes → high morbidity/mortality (protein loss, infection, persistent drainage)

— Refractory → TIPS evaluation, liver transplant referral

Board pearl: Empyema and complicated parapneumonic effusion require BOTH antibiotics AND drainage — antibiotic monotherapy is a guaranteed wrong answer. Conversely, simple parapneumonic effusion (pH >7.20, no organisms) needs antibiotics alone; reflexive chest tube placement is also wrong.

CHF-related transudate:

Parapneumonic effusion / empyema antibiotics:

Hepatic hydrothorax:

Malignant effusion: systemic chemotherapy/targeted therapy directed at primary; intrapleural therapy not routine.

TB pleuritis: standard RIPE 4-drug regimen × 2 months, then RI × 4 months; corticosteroids not routinely beneficial.

Rheumatologic effusion: NSAIDs, corticosteroids; treat underlying disease.

Post-cardiac injury syndrome (Dressler-like): NSAIDs ± colchicine; steroids if refractory.

Procedures — Thoracentesis Technique and Drainage Options

— Position: seated, arms forward on bedside table; supine for ventilated patients with US guidance

— Site: posterior, one interspace below upper level of effusion, along upper border of rib (avoids neurovascular bundle that runs under the rib)

— Always use real-time or marking ultrasound — standard of care

— Local anesthesia with 1% lidocaine through skin, periosteum, and pleura

— Aspirate 30–50 mL for diagnostic studies

— Connect to vacuum bottle or wall suction; drain until symptom resolution, cough, or chest discomfort

— Historically cap at 1.5 L per session; with manometry, stop if pleural pressure < −20 cm H₂O

— Post-procedure CXR not routinely required if asymptomatic and US-guided with no suspicion of pneumothorax; obtain if multiple passes, symptoms, or ventilated

— Pneumothorax (~3–6%, <1% with US)

— Hemothorax (intercostal artery laceration — higher in elderly with tortuous arteries; consider entering more medially with caution)

— Re-expansion pulmonary edema (large-volume rapid drainage of chronic effusion)

— Infection, splenic/hepatic injury

CCS pearl: Order "ultrasound-guided thoracentesis" as the procedure name and simultaneously order pleural fluid protein, LDH, glucose, pH, cell count with differential, Gram stain, culture, cytology plus serum protein, LDH, albumin. Missing the paired serum draw loses points.

Diagnostic thoracentesis:

Therapeutic thoracentesis:

Post-procedure:

Complications:

Tube thoracostomy / chest drain: empyema, complicated parapneumonic, hemothorax, pneumothorax with effusion. Small-bore (10–14 Fr) catheters effective for most empyemas with intrapleural tPA + DNase (MIST-2 trial) improving drainage.

VATS decortication: persistent empyema despite drainage + fibrinolytics, trapped lung.

Indwelling pleural catheter (PleurX): recurrent malignant effusion — drains at home, allows pleurodesis to develop in ~50%.

Chemical pleurodesis: talc slurry/poudrage for recurrent malignant effusion in patients with expandable lung.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of malignant and CHF effusions; lower threshold for tapping unexplained effusion

— Tortuous intercostal arteries increase hemothorax risk — enter more posterior-medial under US guidance; consider color Doppler to identify the artery

— Reduced reserve → drain conservatively to avoid re-expansion pulmonary edema

— Polypharmacy: review anticoagulants/antiplatelets before tap. Current consensus: continue aspirin; hold DOACs typically 24–48 h (longer if CrCl reduced); bridge warfarin only if INR >1.5 and procedure urgent

— Uremia itself causes exudative effusions (lymphocytic, often bilateral) — usually responds to intensified dialysis

— Peritoneal dialysis can produce acute right-sided hydrothorax via diaphragmatic defects — pleural fluid glucose markedly higher than serum is the giveaway

— Drug dosing: levofloxacin, vancomycin, piperacillin-tazobactam all require renal adjustment; avoid nephrotoxins (aminoglycosides) — also poor pleural penetration

— Platelet dysfunction in uremia → consider DDAVP 0.3 mcg/kg pre-procedure if bleeding risk

— Usually right-sided (~85%), can occur without clinically evident ascites

— Pleural fluid mirrors ascitic fluid: low protein, SAAG-like albumin gradient

— Avoid chest tubes — high mortality from protein/electrolyte loss, infection (spontaneous bacterial empyema), and persistent drainage

— Definitive therapy: sodium restriction + diuretics → TIPS → liver transplantation

— Spontaneous bacterial empyema: PMN >250/μL or positive culture → 3rd-gen cephalosporin × 7–10 days

Key distinction: A cirrhotic with a new right-sided effusion and fever — think spontaneous bacterial empyema, not pneumonia. Diagnostic tap with cell count is mandatory; empiric ceftriaxone if PMN >250 even before cultures return.

Elderly:

Renal impairment / ESRD:

Hepatic impairment / cirrhosis (hepatic hydrothorax):

Special Populations — Pregnancy, Pediatrics, Immunocompromised

— Small asymptomatic postpartum effusions occur in up to 25% of normal deliveries — resolve spontaneously

— New symptomatic effusion: think PE (pregnancy is hypercoagulable), preeclampsia with pleural transudate, or amniotic fluid–related

— Imaging: ultrasound first; CXR with abdominal shielding is safe (<0.1 mGy fetal dose); CT-PA if PE suspected — benefits outweigh risk

— Thoracentesis safe in pregnancy; position lateral decubitus or partial sitting to avoid IVC compression

— Avoid fluoroquinolones, tetracyclines; use ceftriaxone/ampicillin-sulbactam for parapneumonic effusion

— Parapneumonic effusion most common cause — S. pneumoniae, S. aureus (including MRSA), S. pyogenes

— Lower threshold for chest tube + intrapleural fibrinolytics or primary VATS — both equivalent outcomes per pediatric guidelines

— Avoid quinolones; use ceftriaxone ± vancomycin/clindamycin

— Broader differential: TB, Pneumocystis, fungal (Cryptococcus, Aspergillus, endemic mycoses), Kaposi sarcoma, lymphoma

— Send AFB smear/culture, ADA, fungal cultures, cryptococcal antigen, cytology, flow cytometry on the tap

— Lymphocyte-predominant exudate in HIV from endemic area → presumptive TB while awaiting cultures; ADA >40 supports

— Small left-sided effusions in ~40–75% in first weeks — usually resolve

— Large or persistent effusion >30 days post-op → tap; often lymphocytic exudate of post-cardiac injury syndrome (treat with NSAIDs + colchicine)

Step 3 management: In a pregnant patient with unilateral pleuritic chest pain and effusion, do not anchor on infection — order D-dimer (less useful in third trimester), lower-extremity Doppler, and CT-PA or V/Q scan. Missed PE is a top obstetric malpractice scenario.

Pregnancy:

Pediatrics:

Immunocompromised (HIV, transplant, chemotherapy):

Post-CABG patients:

Complications and Adverse Outcomes

— Pneumothorax — most common; 3–6% blind, <1% US-guided. Small asymptomatic → observation + repeat CXR in 4–6 h. Large or symptomatic → chest tube

— Hemothorax — intercostal artery laceration; presents with hypotension, falling hemoglobin, expanding effusion. Manage with chest tube; surgical exploration if >200 mL/h drainage or >1500 mL initial

— Re-expansion pulmonary edema — unilateral pulmonary edema after rapid drainage of large/chronic effusion. Risk factors: >1.5 L drained, effusion present >7 days, high negative pleural pressure. Manage with supportive care, supplemental O₂, sometimes mechanical ventilation

— Infection — empyema seeding from procedure; rare

— Visceral injury — spleen (left-sided low taps), liver (right-sided low taps), diaphragm

— Vasovagal syncope, pain

— Trapped lung — visceral pleural fibrosis prevents re-expansion → persistent ex vacuo effusion. Manometry shows precipitous pressure drop (<−20 cm H₂O) with minimal drainage. Definitive treatment: decortication or accept palliative IPC

— Loculation/fibrothorax — chronic restrictive lung disease

— Empyema necessitans — empyema dissecting through chest wall, classic in TB and actinomycosis

— Bronchopleural fistula — air leak persisting >5–7 days post chest tube; consider with empyema

— Chronic pleural thickening — restrictive ventilatory defect, especially post-TB or asbestos

— Recurrent malignant effusions → respiratory failure, decreased QOL

— Untreated empyema → sepsis, death (mortality 10–20%)

Board pearl: Unilateral pulmonary edema localized to the just-drained side hours after thoracentesis is re-expansion pulmonary edema, not CHF — supportive care, do not diurese aggressively. Cap drainage at 1.5 L or use manometry to prevent.

Procedure-related:

Disease-related:

Long-term sequelae:

When to Escalate — ICU, Consult, or Inpatient Triage

— Tension hydrothorax with mediastinal shift and hemodynamic compromise → emergent needle decompression then chest tube

— Massive hemothorax (>1500 mL initial or >200 mL/h ongoing) → thoracic surgery for emergent thoracotomy

— Empyema with sepsis/septic shock → ICU + broad-spectrum antibiotics + urgent drainage + surgery consult

— Re-expansion pulmonary edema with hypoxic respiratory failure → ICU for ventilatory support

— Complicated parapneumonic effusion or empyema requiring chest tube

— Large symptomatic effusion needing drainage with comorbidities

— Significant hypoxia (SpO₂ <90% on RA), respiratory distress

— Diagnostic uncertainty requiring multiple studies

— Hemodynamic instability

— Interventional pulmonology / pulmonology: loculated effusions, suspected malignancy, recurrent effusion, IPC placement, medical thoracoscopy

— Thoracic surgery: persistent empyema (failed drainage at 5–7 days), trapped lung, decortication, VATS pleural biopsy, suspected mesothelioma

— Oncology: malignant effusion management, palliative care planning

— Cardiology: refractory CHF effusion, consideration of advanced therapies

— Infectious disease: TB pleuritis, immunocompromised host, atypical pathogens

— Hepatology: hepatic hydrothorax — TIPS/transplant evaluation

— Small transudate from controlled CHF responding to diuresis

— Stable post-CABG effusion under follow-up

— Asymptomatic chronic effusion under surveillance

CCS pearl: On a CCS case with empyema, order chest tube placement → IV antibiotics → thoracic surgery consult on day 1, not after fibrinolytics fail. Early surgical involvement improves outcomes and shortens length of stay — a recurring CCS scoring trigger.

Immediate ICU / emergent intervention:

Inpatient admission criteria:

Consultations:

Outpatient management appropriate when:

Key Differentials — Within the Pleural Disease Category

— Heart failure — bilateral, right > left; resolves with diuresis; pleural BNP elevated

— Cirrhosis (hepatic hydrothorax) — right-sided in 85%; often without overt ascites; same biochemistry as ascites

— Nephrotic syndrome — bilateral; low oncotic pressure; check for PE (hypercoagulable)

— Atelectasis — small effusion from negative intrapleural pressure

— Peritoneal dialysis — acute right-sided, very high glucose

— Urinothorax — obstructive uropathy; pleural creatinine > serum creatinine, low pH

— Constrictive pericarditis, SVC obstruction, myxedema (myxedema can be transudate or exudate)

— Parapneumonic / empyema — neutrophilic, low glucose, low pH

— Malignancy — lymphocytic, bloody, cytology-positive; lung, breast, lymphoma, ovarian, mesothelioma

— TB pleuritis — lymphocytic, ADA >40, mesothelial cells <5%, AFB smear often negative but culture/biopsy diagnostic

— Pulmonary embolism — small, bloody, exudate; PE found in ~20% of unexplained exudates

— Pancreatitis — left-sided, very high amylase

— Esophageal rupture (Boerhaave) — left-sided, high amylase (salivary), low pH (<6.0), food particles

— Connective tissue disease — RA (very low glucose <30, low pH, high RF), SLE (positive ANA, LE cells)

— Drug-induced — amiodarone, methotrexate, nitrofurantoin, dasatinib

— Chylothorax — milky, triglycerides >110 mg/dL; thoracic duct injury, lymphoma

— Hemothorax — pleural Hct/serum Hct >0.5; trauma, malignancy, anticoagulation

— Post-CABG / post-cardiac injury syndrome — lymphocytic, weeks–months post-op

Key distinction: Lymphocyte-predominant exudate narrows to four big buckets: TB, malignancy, chylothorax, post-CABG. Send ADA, cytology, triglycerides, and review surgical history before pursuing pleural biopsy.

Transudative effusions (Light's: protein <0.5, LDH <0.6):

Exudative effusions:

Key Differentials — Non-Pleural Mimics on Imaging and Exam

— Lobar pneumonia / consolidation — opacification but without meniscus; air bronchograms present; fremitus increased

— Atelectasis (lobar collapse) — volume loss, ipsilateral mediastinal shift toward, elevated diaphragm

— Pleural thickening / fibrothorax — does not layer on decubitus; chronic, often calcified

— Pleural masses / mesothelioma — nodular pleural-based opacity, often with effusion

— Diaphragmatic paralysis / eventration — elevated hemidiaphragm mimics blunting

— Subpulmonic effusion — fluid above diaphragm without blunting CP angle on PA; lateral decubitus confirms

— Hydropneumothorax — air-fluid level with sharp interface

— Lobar pneumonia — dullness, but fremitus increased, egophony, bronchial breath sounds

— Pneumonectomy / post-surgical fluid filling — opaque hemithorax, history is key

— Large lung mass — dullness, decreased breath sounds; CT distinguishes

— Elevated hemidiaphragm from phrenic palsy — dullness at base, but no meniscus

— Pulmonary embolism (may also coexist with small effusion)

— Heart failure without effusion

— COPD/asthma exacerbation

— Pulmonary fibrosis

— Anxiety/hyperventilation

Board pearl: A completely opaque (white-out) hemithorax — distinguish by tracheal position: shifted toward = atelectasis or pneumonectomy; shifted away = massive effusion or large mass; midline = consolidation or mesothelioma. This single rule resolves most opaque-hemithorax stems on Step 3.

Conditions that look like pleural effusion radiographically:

Conditions that mimic effusion on exam:

Causes of dyspnea without effusion that get confused:

Secondary Prevention, Discharge Plan, and Long-Term Management

— Optimize GDMT: ARNI + beta-blocker + MRA + SGLT2 inhibitor for HFrEF; SGLT2 + diuretic + treat comorbidities for HFpEF

— Daily weights, low-sodium diet (<2 g/day), fluid restriction (<2 L/day) if hyponatremic

— Influenza and pneumococcal vaccination

— Cardiac rehab referral

— Complete full antibiotic course (2–6 weeks); confirm radiographic resolution at 4–6 weeks

— Smoking cessation counseling and pharmacotherapy (varenicline, NRT, bupropion)

— Pneumococcal vaccination (PCV20 or PCV15 + PPSV23 per current ACIP), annual influenza, COVID booster

— Dental hygiene optimization (aspiration risk)

— Coordinate with oncology for systemic therapy

— Indwelling pleural catheter care education for patient/family — drainage 2–3×/week

— Palliative care referral early; advance directives discussion

— Complete 6-month RIPE → INH/rifampin regimen with DOT

— Public health notification, contact tracing

— Monthly clinical and LFT monitoring

— Sodium restriction, diuretics, alcohol cessation

— Hepatology referral for TIPS/transplant evaluation; MELD updating

— Avoid NSAIDs (worsen ascites/renal function)

— Pleurodesis or IPC; home health for catheter management

Step 3 management: At discharge after empyema, schedule pulmonology follow-up at 2 weeks with repeat CXR, antibiotic completion plan, vaccination updates, and smoking cessation referral. Failure to document vaccination and smoking cessation is a common Step 3 deduction even when the clinical answer is right.

CHF-related effusion:

Post-empyema / parapneumonic effusion:

Malignant effusion:

TB pleuritis:

Hepatic hydrothorax:

Recurrent malignant or refractory effusion:

Anticoagulation considerations: if post-thoracentesis, can resume DOAC/warfarin in 24 h if no bleeding; aspirin can be continued throughout.

Follow-Up, Monitoring, and Rehabilitation

— Symptom check at 24 h: dyspnea, chest pain, fever

— Repeat CXR only if symptomatic or post-procedure complications suspected

— Pleural fluid results review with patient within 48–72 h

— Weekly weights, daily home BP, electrolytes/creatinine within 1–2 weeks of diuretic changes

— Echocardiogram if not recent (within 6–12 months) or clinical change

— Cardiology follow-up at 1–2 weeks post-discharge

— CXR at 4–6 weeks to confirm resolution; if persistent abnormality, consider underlying malignancy and obtain CT chest

— Pulmonary function testing at 8–12 weeks if symptomatic — assess for restrictive defect from pleural thickening

— Pulmonary rehab if functional limitation

— IPC drainage log; monitor for catheter infection, blockage

— Pleurodesis success assessment at 4–6 weeks

— Oncology follow-up tied to systemic therapy cycles

— Monthly clinical, sputum (if pulmonary involvement), LFTs

— End-of-therapy CXR; residual pleural thickening common but does not require extended treatment

— Re-image at 4–6 weeks; persistent or growing effusion → re-tap and reconsider diagnosis

— Treat with NSAIDs + colchicine if post-cardiac injury syndrome

— Smoking cessation at every visit (5 A's: Ask, Advise, Assess, Assist, Arrange)

— Pulmonary rehabilitation for chronic restrictive disease

— Vaccination (pneumococcal, influenza, COVID, RSV per age) — verify and document

CCS pearl: On CCS, advancing the clock past the acute admission requires explicit follow-up orders: "Follow-up CXR in 4–6 weeks, pulmonology in 2 weeks, smoking cessation counseling, pneumococcal vaccine." Omitting these costs continuity-of-care points.

Post-thoracentesis (outpatient or inpatient):

CHF effusion:

Parapneumonic effusion / empyema:

Malignant effusion:

TB pleuritis:

Post-CABG effusion:

Counseling:

Ethical, Legal, and Patient Safety Considerations

— Discuss risks: pneumothorax (~1% with US, 3–6% without), hemothorax, infection, re-expansion pulmonary edema, organ injury, vasovagal reaction

— Alternatives: observation, imaging-only, chest tube

— Document capacity assessment; for incapacitated patients, surrogate consent per state hierarchy

— Emergency exception applies for tension hydrothorax — implied consent under emergency doctrine

— Wrong-site thoracentesis is a sentinel event. Mandatory pre-procedure time-out: verify patient identity (two identifiers), site (confirm with imaging and US marking), procedure, consent

— Always use ultrasound guidance — the standard of care; failure to use US when available is a legal/quality vulnerability

— Post-procedure handoff: communicate findings, drainage volume, complications, follow-up plan to receiving team using structured tool (I-PASS, SBAR)

— TB pleuritis → notify state/local public health; contact tracing legally required

— Mesothelioma → many states require occupational disease reporting; document asbestos exposure history meticulously for potential compensation

— Pleural fluid cytology/microbiology often results after discharge — establish a tracking system; patient must know how/when results will be communicated

— Failure to follow up cytology returning positive for malignancy after discharge is a high-yield malpractice scenario

— Recurrent malignant effusion: discuss palliative care, IPC vs pleurodesis, hospice eligibility

— Honor advance directives; do not perform repeat invasive procedures inconsistent with goals

Step 3 management: A patient with a malignant effusion declines further drainage and requests hospice. This is an autonomous, capacitated decision — honor it, arrange palliative care, and document discussion. Pursuing further intervention despite refusal violates autonomy and is the wrong answer.

Informed consent for thoracentesis:

Patient safety / "never events":

Mandatory reporting:

Transition of care risks:

End-of-life and goals of care:

Equity considerations: ensure interpreter for non-English-speaking patients during consent; document use.

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: The single highest-yield Step 3 trigger: parapneumonic effusion pH <7.20 OR glucose <60 OR positive Gram stain → chest tube + antibiotics, not antibiotics alone.

Bilateral effusions → CHF, nephrotic syndrome, hypoalbuminemia, drug-induced, lupus

Right-sided isolated effusion → hepatic hydrothorax, ascending diaphragmatic process

Left-sided isolated effusion → pancreatitis, esophageal rupture, post-CABG, ruptured ectopic AAA, chylothorax (thoracic duct above T5 → left)

Glucose <30 → RA effusion (lowest glucose of any cause); also empyema, malignancy, TB

pH <7.20 → drain it (complicated parapneumonic)

pH <6.0 → esophageal rupture

Amylase elevated → pancreatitis, esophageal rupture, malignancy

Triglycerides >110 → chylothorax (lymphoma is most common atraumatic cause)

Cholesterol >200, no chylomicrons → pseudochylothorax (chronic effusion, TB, RA)

ADA >40 → TB pleuritis

Bloody effusion (Hct pleural <50% serum) → malignancy, PE, trauma, post-CABG

Hct pleural/serum >0.5 → hemothorax → chest tube

Eosinophils >10% → air/blood in pleural space, drug reaction, asbestos, parasites, fungal

Mesothelial cells absent (<5%) in lymphocytic effusion → suggests TB

NT-proBNP pleural >1500 → CHF

Pleural fluid creatinine > serum creatinine → urinothorax

"Split pleura" sign on CT → empyema

Trapped lung → pressure < −20 cm H₂O after small drainage; consider IPC

Asbestos exposure → benign pleural plaques (20+ years latency, no malignant potential alone), benign asbestos effusion, mesothelioma (latency 30–40 years)

Yellow nail syndrome → triad of yellow nails, lymphedema, pleural effusion

Meigs syndrome → benign ovarian fibroma + ascites + right pleural effusion (resolves with tumor resection)

Dressler syndrome → post-MI pericarditis ± pleural effusion, weeks later

Board Question Stem Patterns

— Cue: rising WBC, new effusion on CXR

— Trap: broadening antibiotics

— Answer: diagnostic thoracentesis with pH; if <7.20 or empyema → chest tube

— Cue: 5 days of furosemide, weight down, but right effusion remains

— Trap: continue diuresis

— Answer: thoracentesis — exclude malignancy, PE, infection

— Cue: ascites, no pulmonary infiltrate

— Trap: treat as pneumonia

— Answer: thoracentesis → if PMN >250/μL → spontaneous bacterial empyema → ceftriaxone

— Trap: empyema, malignancy

— Answer: post-cardiac injury syndrome → NSAIDs + colchicine

— Trap: MI, PE

— Answer: Boerhaave → left effusion, high amylase, pH <6.0 → emergent surgery

— Answer: malignant effusion → IPC or pleurodesis; oncology referral

— Answer: TB pleuritis → RIPE × 2 then RI × 4; public health notification

— Answer: re-expansion pulmonary edema → supportive care; prevent by limiting to 1.5 L

— Answer: rheumatoid pleurisy (lowest glucose of all)

— Answer: chylothorax → triglycerides >110; thoracic duct injury; low-fat diet + octreotide, surgery if persistent

Step 3 management: The pivot in nearly every stem is "what do you do next" — and 80% of the time the correct answer involves either ordering a thoracentesis with the right fluid studies or escalating drainage based on pH/glucose/Gram stain. Master that pivot.

Stem 1 — "Hospitalized for pneumonia, persistent fever day 4":

Stem 2 — "CHF patient diuresed, unilateral effusion persists":

Stem 3 — "Cirrhotic with new right effusion and fever":

Stem 4 — "Post-CABG, left effusion 6 weeks later, lymphocytic":

Stem 5 — "Severe pleuritic chest pain, vomiting, mediastinal air":

Stem 6 — "Smoker with recurrent bloody right effusion, cytology positive":

Stem 7 — "Immigrant from endemic area, lymphocytic exudate, ADA 75":

Stem 8 — "Unilateral pulmonary edema after draining 2.5 L":

Stem 9 — "RA patient with effusion, glucose 15":

Stem 10 — "Milky white pleural fluid post-thoracic surgery":

One-Line Recap

A new, clinically significant pleural effusion of unclear etiology demands ultrasound-guided thoracentesis with paired serum studies, applying Light's criteria to separate transudate (treat the systemic cause) from exudate (chase the differential), and any parapneumonic effusion with pH <7.20, glucose <60, positive Gram stain, or loculation requires chest-tube drainage on top of antibiotics.

Light's criteria — exudate if ANY: pleural/serum protein >0.5, pleural/serum LDH >0.6, pleural LDH >2/3 ULN serum. 25% of diuresed CHF effusions misclassified — rescue with serum–pleural protein gradient >3.1, albumin gradient >1.2, or pleural NT-proBNP >1500.

Drain triggers in parapneumonic effusion: pH <7.20, glucose <60, positive Gram stain/culture, loculation, frank pus (empyema). Empyema = chest tube + antibiotics ± intrapleural tPA/DNase ± VATS.

Fluid-marker shortcuts: glucose <30 → RA; amylase up → pancreatitis/esophageal rupture; pH <6 → Boerhaave; TG >110 → chylothorax; ADA >40 → TB; Hct pleural/serum >0.5 → hemothorax; pleural creatinine > serum → urinothorax.

Safety + Step 3 essentials: always use ultrasound guidance, cap therapeutic drainage at ~1.5 L (or use manometry) to prevent re-expansion pulmonary edema, document informed consent and pre-procedure time-out, track post-discharge cytology and culture results, report TB to public health, and on discharge optimize vaccinations (pneumococcal, influenza), smoking cessation, and GDMT where applicable. On CCS, order CXR → bedside US → US-guided thoracentesis with paired serum protein/LDH/albumin and full pleural panel, then escalate to chest tube and thoracic surgery early for empyema.